AveXis Issues Detailed Response to Zolgensma Form 483

Drug GMP Report
A A
Novartis subsidiary AveXis placed the blame for data manipulation over its $2 million spinal muscular atrophy drug Zolgensma squarely on two former senior executives, in a lengthy response to the FDA’s Form 483 inspection observations.

To View This Article:

Login

Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00